Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD) - Tabular View

Tracking Information
First Received Date ^ICMJE	July 3, 2001
Last Updated Date	January 20, 2009
Start Date ^ICMJE	November 1999
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00018603 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)
Official Title ^ICMJE	Guanfacine for the Treatment of PTSD
Brief Summary	This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.
Detailed Description	Subject population is comprised of 100 persons with PTSD. 50 patients will receive guanfacine and 50 patients will receive a placebo. Guanfacine is prescribed at 1 mg/day and may be increased to 2 mg/day. Samples of plasma MHPG will be collected weekly. Clinical ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly. Repeated measures analysis of variance will assess significance of main effect of drug, time, and drug by time.
Study Phase	Phase I
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Condition ^ICMJE	Post-Traumatic Stress Disorder
Intervention ^ICMJE	Drug: guanfacine
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date	October 2002
Primary Completion Date
Eligibility Criteria ^ICMJE	Males and females, age 18-65 Diagnosis of PTSD from combat or civilian trauma No major medical problems such as diabetes, cardiovascular disease Taking no psychiatric medication, or taking only one SSRI antidepressant
Gender	Both
Ages	18 Years to 65 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00018603
Responsible Party
Study ID Numbers ^ICMJE	MHBS-047-99F
Study Sponsor ^ICMJE	Department of Veterans Affairs
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Department of Veterans Affairs
Verification Date	December 2004
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP